newsfilter
← Latest News
GlobeNewswire·

Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026

  • Biofrontera Inc. (NASDAQ: BFRI) will report Q3 2026 financial results before market open on Friday, November 13, 2026.
  • Management will host a conference call & webcast on November 13, 2026, at 10:00 a.m. Eastern Time to discuss results & provide a business update.
  • The company develops, manufactures, & commercializes products for dermatological conditions, specifically focusing on photodynamic therapy.
  • Biofrontera's products include Ameluz ® & RhodoLED ® Lamps used to treat actinic keratosis & superficial basal cell carcinoma.
  • The U.S. Food and Drug Administration approved the treatment of superficial basal cell carcinoma in September 2026.
  • Investor contact for the company is Ben Shamsian at Lytham Partners.
Company
Biofrontera Inc.
Keywords
Nasdaq:BFRI , Biofrontera Inc., Biofrontera Inc., NASDAQ: BFRI, Third Quarter 2026, Financial Results, biopharmaceutical company, pharmaceutical products, Ameluz®